Advanced Accelerator Applications

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Advanced Accelerator Applications sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 3 completed early-phase tilt upper quartile by trial count

Advanced Accelerator Applications: 8 sponsored US clinical trials, none currently recruiting.

Advanced Accelerator Applications sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastroenteropancreatic Neuroendocrine Tumors, with 1 trials.

Upper-quartile sponsor footprint

Advanced Accelerator Applications sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT04711135
ACTIVE NOT RECRUITING Phase 3

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
ACTIVE NOT RECRUITING

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064
COMPLETED Phase 1

[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

NCT03872778
TERMINATED Phase 1

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

NCT03490838
COMPLETED Phase 1

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

NCT03490032
TERMINATED Phase 2

99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis

NCT03232580
COMPLETED Phase 3

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

NCT01578239

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2
Phase 3 2

Therapeutic Areas

Gastroenteropancreatic Neuroendocrine Tumors 1
Neuroendocrine Tumors 1
Pheochromocytoma 1
Paraganglioma 1
Neoplasms 1
Gastroenteropancreatic Neuroendocrine Tumor 1

How the Advanced Accelerator Applications early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 3 completed (38%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Gastroenteropancreatic Neuroendocrine Tumors (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Advanced Accelerator Applications: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Advanced Accelerator Applications sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Advanced Accelerator ApplicationsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Advanced Accelerator Applications sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Advanced Accelerator Applications sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Advanced Accelerator Applications page

8 registered trials is a research-attention snapshot, not an endorsement of Advanced Accelerator Applications or any single study.

  • None of Advanced Accelerator Applications's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Gastroenteropancreatic Neuroendocrine Tumors is the condition Advanced Accelerator Applications studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gastroenteropancreatic Neuroendocrine Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Advanced Accelerator Applications pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.